Tg Therapeuticscmn (TGTX)
WEIGHTED MOVING AVERAGE
Trading: SELL @ $4.88
Signal Strength: STRONG
Indicator can be used in isolation or in additional to another technical indicator to confirmation for trading entry. This indicator has the ability to highlight trends across numerous timeframes. This indicator has the ability to smooth historical results to illustrate trend initiation and status. Although this is a simple trend following indicator & can provide good results when coupled with the right indicator. Note, this indicator does not work well in ranging markets producing unwanted whipsaws and false signals.
Tg Therapeuticscmn (NASDAQ:TGTX) currently has a confirmed downtrend. Recent trading has caused the WMA 15 day average to move below the closing price confirming the short term trend following indicator. Currently, the return on WMA15 is -5.4%.
Weighted moving averages (WMA) are difficult to construct but more reliable than the simple moving averages. WMA permits an unequal weighting on prior time periods.
Calculation: Weighted Moving Average (WMA):
1) Ft= W1At-1 + WnAt-n
PROFILE: Tg Therapeuticscmn (TGTX)
Stock Exchange: NASDAQ
Company: Tg Therapeuticscmn
Ticker Codes: | TGTX | NASDAQ:TGTX |
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
Weighted Moving AverageDownload
|AKAO Achaogen Inc||1.95||8.3||1,429,545||-10.6||BEARISH|
|CSII Cardiovascular Syst||30.23||5||383,299||0||BEARISH|
|WVE WAVE Life Sciences||40.76||4.8||83,673||-1.6||BEARISH|
|NVDA Nvidia Corporation||149.08||3||41,918,325||-19.6||BEARISH|
|OSUR Orasure Tech Inc||12.79||2.9||1,069,412||-2.6||BEARISH|
|ALGN Align Technology||210.1||2.8||3,364,755||-5.7||BEARISH|
|FORM Formfactor Inc||14.58||2.8||965,235||-0.3||BEARISH|